La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Soligenix Résultats passés
Passé contrôle des critères 0/6
Soligenix has been growing earnings at an average annual rate of 7.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 45.6% per year.
Informations clés
7.8%
Taux de croissance des bénéfices
33.3%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | -45.6% |
Rendement des fonds propres | -203.3% |
Marge nette | -1,423.8% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma
Oct 05U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer
Sep 12Soligenix announces $2.6M FDA grant to further study blood cancer candidate
Sep 06Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Sep 06Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M
Aug 12Soligenix, SERB Pharma team up to develop therapy for ricin poisoning
Jul 25Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Apr 22Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?
Jan 03Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now
Sep 17Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?
Aug 30Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?
May 08What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 16Soligenix inks supply and distribution deal for SGX301 companion light device in cancer
Jan 07Soligenix receives $1.5M grant advancing COVID-19 vaccine development
Dec 28Ventilation des recettes et des dépenses
Comment Soligenix gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 0 | -7 | 5 | 3 |
31 Mar 24 | 1 | -7 | 4 | 3 |
31 Dec 23 | 1 | -6 | 4 | 3 |
30 Sep 23 | 1 | -8 | 5 | 5 |
30 Jun 23 | 1 | -10 | 5 | 6 |
31 Mar 23 | 1 | -10 | 5 | 7 |
31 Dec 22 | 1 | -14 | 7 | 8 |
30 Sep 22 | 1 | -15 | 7 | 8 |
30 Jun 22 | 1 | -15 | 7 | 9 |
31 Mar 22 | 1 | -15 | 7 | 9 |
31 Dec 21 | 1 | -13 | 5 | 8 |
30 Sep 21 | 1 | -13 | 5 | 9 |
30 Jun 21 | 1 | -12 | 5 | 8 |
31 Mar 21 | 2 | -12 | 4 | 8 |
31 Dec 20 | 2 | -18 | 4 | 15 |
30 Sep 20 | 3 | -15 | 3 | 13 |
30 Jun 20 | 3 | -16 | 3 | 14 |
31 Mar 20 | 4 | -15 | 3 | 14 |
31 Dec 19 | 5 | -9 | 3 | 8 |
30 Sep 19 | 5 | -10 | 3 | 8 |
30 Jun 19 | 5 | -9 | 3 | 7 |
31 Mar 19 | 5 | -8 | 3 | 7 |
31 Dec 18 | 5 | -9 | 3 | 7 |
30 Sep 18 | 6 | -8 | 3 | 6 |
30 Jun 18 | 6 | -7 | 3 | 5 |
31 Mar 18 | 5 | -8 | 3 | 6 |
31 Dec 17 | 5 | -7 | 3 | 6 |
30 Sep 17 | 6 | -5 | 3 | 4 |
30 Jun 17 | 7 | -6 | 3 | 5 |
31 Mar 17 | 9 | -4 | 3 | 4 |
31 Dec 16 | 10 | -3 | 3 | 4 |
30 Sep 16 | 12 | -5 | 4 | 5 |
30 Jun 16 | 13 | -1 | 4 | 5 |
31 Mar 16 | 11 | -4 | 4 | 6 |
31 Dec 15 | 9 | -8 | 4 | 5 |
30 Sep 15 | 8 | -4 | 3 | 5 |
30 Jun 15 | 7 | -11 | 3 | 5 |
31 Mar 15 | 7 | -8 | 3 | 5 |
31 Dec 14 | 7 | -7 | 3 | 5 |
30 Sep 14 | 6 | -8 | 3 | 4 |
30 Jun 14 | 4 | -10 | 3 | 4 |
31 Mar 14 | 3 | -12 | 3 | 5 |
31 Dec 13 | 3 | -10 | 3 | 5 |
30 Sep 13 | 3 | -12 | 3 | 5 |
Des revenus de qualité: SNGX is currently unprofitable.
Augmentation de la marge bénéficiaire: SNGX is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: SNGX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.
Accélération de la croissance: Unable to compare SNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: SNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement des fonds propres
ROE élevé: SNGX has a negative Return on Equity (-203.26%), as it is currently unprofitable.